KR20210102259A - 면역조절을 이용한 암 치료를 위한 신규한 접근법 - Google Patents

면역조절을 이용한 암 치료를 위한 신규한 접근법 Download PDF

Info

Publication number
KR20210102259A
KR20210102259A KR1020217018080A KR20217018080A KR20210102259A KR 20210102259 A KR20210102259 A KR 20210102259A KR 1020217018080 A KR1020217018080 A KR 1020217018080A KR 20217018080 A KR20217018080 A KR 20217018080A KR 20210102259 A KR20210102259 A KR 20210102259A
Authority
KR
South Korea
Prior art keywords
treatment
pembrolizumab
talabostat
administered
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217018080A
Other languages
English (en)
Korean (ko)
Inventor
빈센트 제이 오닐
Original Assignee
바이오엑셀 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오엑셀 테라퓨틱스 인코포레이티드 filed Critical 바이오엑셀 테라퓨틱스 인코포레이티드
Publication of KR20210102259A publication Critical patent/KR20210102259A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020217018080A 2018-12-10 2019-12-10 면역조절을 이용한 암 치료를 위한 신규한 접근법 Withdrawn KR20210102259A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862777352P 2018-12-10 2018-12-10
US62/777,352 2018-12-10
US201962924429P 2019-10-22 2019-10-22
US62/924,429 2019-10-22
PCT/US2019/065465 WO2020123496A1 (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Publications (1)

Publication Number Publication Date
KR20210102259A true KR20210102259A (ko) 2021-08-19

Family

ID=71075816

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217018080A Withdrawn KR20210102259A (ko) 2018-12-10 2019-12-10 면역조절을 이용한 암 치료를 위한 신규한 접근법

Country Status (13)

Country Link
US (1) US20220089733A1 (https=)
EP (1) EP3893869A4 (https=)
JP (2) JP2022512158A (https=)
KR (1) KR20210102259A (https=)
CN (1) CN113260361A (https=)
AU (1) AU2019396206A1 (https=)
BR (1) BR112021011205A2 (https=)
CA (1) CA3121270A1 (https=)
IL (1) IL283742A (https=)
MX (1) MX2021006778A (https=)
SG (1) SG11202106129RA (https=)
TW (1) TW202034955A (https=)
WO (1) WO2020123496A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2021158884A1 (en) * 2020-02-07 2021-08-12 Bioxcel Therapeutics, Inc. Treatment regimen for cancer using immunomodulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033368A2 (en) * 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
CA2973040A1 (en) * 2015-01-09 2016-07-14 Mabimmune Diagnostics Ag Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2017058881A1 (en) * 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
US11613785B2 (en) * 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法

Also Published As

Publication number Publication date
JP2025156353A (ja) 2025-10-14
EP3893869A1 (en) 2021-10-20
TW202034955A (zh) 2020-10-01
JP2022512158A (ja) 2022-02-02
WO2020123496A1 (en) 2020-06-18
CN113260361A (zh) 2021-08-13
BR112021011205A2 (pt) 2021-08-24
EP3893869A4 (en) 2022-08-17
SG11202106129RA (en) 2021-07-29
IL283742A (en) 2021-07-29
MX2021006778A (es) 2021-07-15
US20220089733A1 (en) 2022-03-24
AU2019396206A1 (en) 2021-06-17
CA3121270A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
US20250019388A1 (en) Stat3 degraders and uses thereof
KR102610764B1 (ko) 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합
JP2025156353A (ja) 免疫調節を使用したがんの治療のための新規アプローチ
EP3934689B1 (en) An antibody for use in methods of treating al amyloidosis
US20230338402A1 (en) Treatment regimen for cancer using immunomodulation
WO2022109302A9 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
TW202346335A (zh) 治療al類澱粉變性症之方法
WO2023136837A1 (en) Use of tivozanib and durvalumab for treating hepatocellular carcinoma (hcc)
US20240307397A1 (en) Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma
Siu Sitravatinib (MGCD516) and Nivolumab in Oral cavity cancer Window opportunity study (SNOW)
Subudhi A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC)
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
TW202513098A (zh) 治療癌症之方法
TW202547553A (zh) 治療ａｌ類澱粉變性症之方法
WO2025260061A1 (en) Compositions and methods for cancer therapy
WO2024258916A1 (en) Stat3 degraders and uses thereof
TW202612702A (zh) 吡啶并［２，３－ｄ］嘧啶－２（１Ｈ）－酮類衍生物聯合用藥在治療和預防腫瘤疾病中的用途
Johnson Phase II Study of Durvalumab (MEDI4736)(anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer.
WO2025242031A1 (zh) 吡啶并[2,3-d]嘧啶-2(1H)-酮类衍生物联合用药在治疗和预防肿瘤疾病中的用途
HK40108543A (zh) 在癌症疗法中使用的抗半乳糖凝集素-9抗体和化疗剂的组合
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
KN026 et al. A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of KN026 in Combination with Chemotherapy in Subjects with HER2-positive Gastric Cancer (including Adenocarcinoma of Esophagogastric Junction) Who Have Failed First-line Treatment
EA043796B1 (ru) Лечение гепатоцеллюлярной карциномы, которая характеризуется вирусной инфекцией гепатита b
NZ795674A (en) Combinations of cabozantinib and atezolizumab to treat cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210611

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221201

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20241010

WITB Written withdrawal of application